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In many cell types, growth factor removal induces the release of cytochrome-c from mitochondria that leads to activation of
caspase-9 in the apoptosome complex. Here, we show that sustained stimulation of the Raf-1/MAPK1,3 pathway prevents caspase-
9 activation induced by serum depletion in CCL39/ΔRaf-1:ER ﬁbroblasts. The protective eﬀect mediated by Raf-1 is sensitive to
MEK inhibition that is suﬃcient to induce caspase-9 cleavage in exponentially growing cells. Raf-1 activation does not inhibit
the release of cytochrome-c from mitochondria while preventing caspase-9 activation. Gel ﬁltration chromatography analysis
of apoptosome formation in cells shows that Raf-1/MAPK1,3 activation does not interfere with APAF-1 oligomerization and
recruitment of caspase 9. Raf-1-mediated caspase-9 inhibition is sensitive to emetine, indicating that the protective mechanism
requires protein synthesis. However, the Raf/MAPK1,3 pathway does not regulate XIAP. Taken together, these results indicate that
the Raf-1/MAPK1,3 pathway controls an apoptosis regulator that prevents caspase-9 activation in the apoptosome complex.
1.Introduction
Apoptosis or programmed cell death is required to maintain
cell homeostasis in multicellular organisms [1], its role is
e s s e n t i a ld u r i n ge m b r y o g e n e s i sa sw e l la si nm a n yp h y s i o -
logicalprocesses,likeimmuneresponses.Thecomponentsof
the apoptotic machinery are expressed in every living cell but
remain inactive thanks to environmentally regulated survival
signaling pathways [2]. Deregulation of apoptosis control is
associated with pathologic processes like neurodegenerative
diseases or cancer [3, 4]. Apoptosis execution requires
activation of the caspase cascade, which is initiated by two
major death-signaling pathways [5]. The extrinsic pathway
leads to the activation of caspase 8 after stimulation of cell
surface death receptors and the intrinsic pathway, which
depends on mitochondrial membrane disruption, leads to
caspase 9 activation. Mitochondrial membrane integrity is
controlled by the ratio of pro- and anti-apoptotic members
of the Bcl2 protein family [6]. The proapoptotic Bcl2
members like Bax Bad or Bim are involved in the release
of apoptogenic proteins such as cytochrome c, smac, and
Omi/HTrA2 in the cytosol [7]. Cytosolic cytochrome c
binds to apoptotic protease activating factor 1 (APAF-1) and
induces the formation of an APAF-1-cytochrome c heptamer
complex [8] or apoptosome. This event is regulated by the
oncoprotein prothymosin α [9] and heat-shock proteins
[10]. Apoptosome recruits and facilitates the autoproteolytic
activationofcaspase9byhomodimerization[11].Onceacti-
vated, caspase 9 cleaves and activates eﬀector caspases such
as caspase 3 and 7 which in turn cleave numerous cellular
substrates, ﬁnalizing the process of cell death. Caspase 9
activationiscontrolledbyaputativetumorsuppressorPHAP
[9] and by the binding of X-linked inhibitor of apoptosis
(XIAP) [12]. In turn, XIAP is inhibited by the mitochondrial
proapoptotic protein Smac/DIABLO and HtrA2/OMI, when
they are released into the cytosol [13].
In tissue cell culture, continuous activation of growth
factor-stimulated survival pathways is required to pre-
vent apoptosis since growth factors withdrawal induces a
metabolic arrest [14] that activates the intrinsic pathway2 Journal of Signal Transduction
of apoptosis and caspase 9. Among the signaling pathways
controlled by serum growth factors, the Raf-1/MAPK path-
way has been shown to play important roles in cell survival
[15]. Knockout studies in mice reveal that raf-1 and b-raf
are involved in developmental cell survival [16]. In human,
constitutive activation of MAPK1,3 pathway by Ras or B-Raf
oncogenes, is implicated in inhibition of apoptosis in tumor
cells, especially in leukemia and melanoma [17, 18].
The MAPK1,3 pathway is involved in the control of
Bcl2 family proteins. MAPK1,3 activation has been found
to increase the expression of the anti-apoptotic proteins
Bcl2, BclXL, and Mcl-1 [19, 20] by transcriptional and post-
translational mechanisms. On the other hand, the MAPK1,3
pathway inactivates proapoptotic members like Bad and Bax
by phosphorylation [21] and enhances degradation of Bim
by the proteasome [22]. The Raf-1/MAPK1,3 pathway has
also been implicated in caspase inhibition downstream of
cytochromecrelease[23–25].Apotential targetof MAPK1,3
i sc a s p a s e9w h o s ea c t i v a t i o nin vitro is inhibited through
direct phosphorylation at Thr 125 by MAPK1 [26]. Caspase
9 was shown to be transiently phosphorylated upon MAPK
activation in intact cells but there is not yet evidence that
this phosphorylation event prevents the processing of the
proform during apoptosis induction. In CCL39 Raf-1:ER
cells, we and others have shown that sustained activation of
MAPK1,3 pathway inhibits matrix detachment and serum
deprivation-induced apoptosis [27, 28].
In this study, we further investigated the mechanism
by which MAPK1,3 activation blocks serum deprivation-
induced caspase 9 cleavage. We show that caspase 9 inhibi-
tion requires MEK activity and protein synthesis. This anti-
apoptotic eﬀect occurs downstream of cytochrome c release
and does not interfere with APAF-1 oligomerization or
caspase9recruitmentintohighmolecularweightcomplexes.
Furthermore we show that the expression levels of XIAP
do not correlate with protein synthesis-dependent caspase
9 inhibition. These results indicate that the Raf-1/MAPK1,3
pathway blocks caspase 9 activation in the apoptosome.
2.MaterialandMethods
2.1. Reagents. The MEK inhibitor U0126 was obtained
from Promega (Madison, WI), PD98059, emetine, 4-
hydroxytamoxifen (4-HT) and the mouse monoclonal anti-
activated MAPK (Sigma M8159; 1:10,000) were from Sigma
(St.Louis, MO).PD184352 waskindly provided byProfessor
PC o h e n( M R CU n i v e r s i tyo fD u n d e e ,U K ) .T h em o n o c l o n a l
anti-poly (ADP-ribose) polymerase (anti-PARP) anti-body
(Signal Transduction SA-250 1:2,000) and caspase 9 peptide
substrate Ac-LEHD-pNA were purchased from Biomol (Ply-
mouth Meeting, PA). Other anti-bodies used include rabbit
polyclonal anti-MAPK1 (1:5,000) [29], mouse monoclonal
anti-denaturated cytochrome c (Pharmingen BD biosciences
San Jose CA, 556433, 1:2,000), rabbit polyclonal anti-active
caspase 3 (Cell Signaling Technology Danvers MA, 9661
1:200), mouse monoclonal anti-caspase 9 (MBL Woburn
MA M054-3 1:2,000) and mouse monoclonal anti-XIAP
(Transduction Laboratories BD biosciences San Jose CA,
1:250).
2.2. Cell Culture. CCL39-ΔRaf-1:ER cells (clone S18) [30]
Chinese hamster ﬁbroblasts stably express an estradiol-
regulated form of oncogenic Raf-1 kinase (plasmids were
kindly provided by Dr. M. McMahon, University of Cal-
ifornia San Francisco Cancer Center, San Francisco, CA).
CCL39-ΔRaf-1:ERcellswerecultivatedinDMEM(LifeT ech-
nologies,Gaithersburg,MD)withoutphenolredandsupple-
mented with penicillin (50U/ml), streptomycin (50μg/ml),
7.5% fetal calf serum (FCS), and G418 (400μg/ml).
2.3. SDS-PAGE and Western Blot Analysis. Adherent and
ﬂoating cells were lysed in Laemmli sample buﬀer, sonicated
15 seconds, and incubated at 65◦Cf o r1 5m i n u t e s .T h i s
protocol, recommended by the manufacturer of the anti-
PARP anti-body for detection of PARP cleavage, was used
for all immunoblot experiments. Proteins were separated by
SDS-PAGE and transferred to PVDF membranes (Millipore
Billerica MA). Dry blots were blocked in 3% dry milk
(dissolved in water for 10 minutes at room temperature),
incubated overnight at 4◦C with the primary anti-body,
washed 5 minutes with tap water. After blocking again,
membranes were incubated 1 hour at 4◦C with horseradish
peroxidase—(HRP,1:40,000)oralkalinephosphatase—(AP,
1:2,000) conjugated secondary anti-bodies (Cell Signaling
Technology, Beverly, MA). Immune complexes were detected
by autoradiography following enhanced chemiluminescence
with SuperSignal (Pierce Thermo Fisher Rockford IL) for
HRP or CDP-star (NEB Beverly, MA) for AP.
2.4.FractionationbyGelFiltration. Thecelllysates(100,000g
supernatant) were prepared by resuspending cells in a
buﬀer containing 50mM PIPES/KOH, 2mM EDTA, 0.1%
(w/v) CHAPS, 5mM dithiothreitol and a protease inhibitor
cocktail (Roche). After a freeze/thaw cycle in liquid nitro-
gen, the lysates were fractionated by size-exclusion chro-
matography using a fast protein liquid chromatography
protein puriﬁcation system (Amersham Pharmacia Biotech
GE Buckinghamshire UK) on an analytical (16/60) Hi
Prep S300 Sephacryl high-resolution column (Amersham
Pharmacia Biotech). The column was pre-equilibrated with
5% (w/v) sucrose, 0.1% (w/v) CHAPS, 20mM HEPES,
5mM dithiothreitol, pH 7.0. All separations were carried
o u ta tr o o mt e m p e r a t u r e .T h ec o l u m nw a sc a l i b r a t e dw i t h
gel ﬁltration protein standards from Sigma (thyroglobulin
MW = 669,000, ferritin MW = 443,000, βamylase MW
= 200,000, alcohol dehydrogenase MW = 150,000, bovine
serum albumin MW = 66,000 ).
Lysates (5mg of protein) were applied to and eluted from
the column at a ﬂow rate of 0.4ml/min, 500μl fractions were
collected and stored at −70◦C.
2.5. Enzymatic Assay for Caspase 9 Activity. Cell lysates
(100,00g fraction of supernatant) were prepared by resus-
pendingcellsfor20minutesat4◦Cinbuﬀercontaining0.1%
(w/v) CHAPS, 0.5% Nonidet P-40, 50mM HEPES pH 7.4,
100M NaCl, 1mM EGTA, and 10mM dithiothreitol. Cell
lysates (200μg protein) were incubated with 200μMc a s p a s e
9 peptide substrate Ac-LEHD-pNA at 37◦Cf o r1h o u r .Journal of Signal Transduction 3
The pNA light emission was quantiﬁed using a microtiter
plate reader at 405nm (Labsystems iEMS Reader MF
Helsinky Finland).
2.6. In Vitro Activation of Caspase 9. Cell lysates were pre-
pared by resuspending cells for 20 minutes at 4◦Ci nb u ﬀer A
(20mM HEPES pH 7.4 10mM KCl, 1.5mMMgCl2 ,1m M
EGTA, and 5mM dithiothreitol) followed by centrifugation
at 10,000g for 20 minutes. Aliquots of the supernatant
containing 5mg/ml protein were frozen in liquid nitrogen
and kept at −70◦C. Activation of caspase 9 was induced
by the addition of 1μM bovine heart cytochrome c (Sigma
St Louis MI) and 1mM ATP (Fermentas Thermo Fisher
Rockford IL) to 20μl cell lysate and incubated at 20◦C, the
reaction was stopped by addition of 2% SDS.
2.7. Immunoﬂuorescence Assays. C e l l sw e r eﬁ x e di n3 %
paraformaldehyde, permeabilized with PBS/0.2% Triton and
blocked with PBS/10% FCS. Cells were stained for 1 hour
with an anti-cytochrome c monoclonal mouse anti-body
(Pharmingen 556432 1:200) and with an anti-active caspase
3 rabbit polyclonal anti-body (Cell Signaling 9661 1:200).
Cells were washed twice with PBS and blocked again with
PBS/10% FCS before staining for 1 hour with Alexa-594
coupled anti-mouse anti-body, Alexa-488 coupled anti-
rabbit anti-body from Molecular Probes (Eugene, OR).
Nuclei were stained for 15 minutes with 50ng/ml 4 ,6-
diamidino-2-phenylindole dihydrochloride (DAPI; Roche,
Hertforshire, United Kingdom). Fluorescence was observed
on a Zeiss inverted microscope (Axiovert 200M) equipped
with a CoolSnap HQ cooled charge-coupled-device camera
(Roper Scientiﬁque, Every, France). Image acquisition and
analysis was performed using the MetaMorph Imaging
System (Universal Imaging Corp. Buckinghamshire UK).
2.8. Caspase 9 Expression Vectors. Caspase 9 was cloned in
Topo vector (Invitrogen) following RT-PCR ampliﬁcation
from HeLa cell total RNA. PCR primers ﬂanking the
coding sequence were designed from the sequence U60521
(genbank)[31]andcorrespondtont14–34AGGCGGCCTG-
GAGTCTTAGTT and nt1311–1329 ACCCTGCCTTAT-
CTTGCAC.ABamHIrestrictionsitewasintroducedbyPCR
at the initiation codon and the BamHI/EcoRI insert was
cloned in pCMV-tag 3B (Stratagene) to introduce the tag
myc in N-terminal. A potential MAPK1,3 phosphorylation
site at Thr 125 was detected using the Phosphobase algo-
rithm at high stringency http://phospho.elm.eu.org/.T h e
threonine was replaced by an alanine using Quick Change
mutagenesis kit (Quiagen Hilden Germany). To derive
stable cell lines expressing these constructs, the catalytic
cysteine (C287) was replaced by a serine. Transfections were
performed by the DNA-calcium phosphate coprecipitation
method.
2.9. 2D Gel Analysis. Cells were lysed with 1 vol 10mM
Tris, 1mM EDTA, 0.5% CHAPS containing phosphatase and
protease inhibitors. Proteins were precipitated by addition
of 3 vol acetone at −20◦C and collected at 10000g for 10
minutes.Thepelletswereresuspendedat10–20mg/mlinIEF
sample buﬀer (7M urea, 2M thiourea, 2% CHAPS, 40mM
Tris and ampholytes). The ﬁrst dimension was performed in
a Zoom IPG Runner (Invitrogen) on pH 4–7, 7cm strips.
The transfer blots and corresponding autoradiograms were
aligned using amido black staining of the PI calibration
markers (creatine phosphokinase carbamylyte, Amersham
pharmacia Biotech Buckinghamshire UK).
3. Results
3.1. Raf-1 Activation Prevents Caspase 9 Cleavage upon Serum
Withdrawal. In exponentially growing CCL39-ΔRaf-1:ER
cells, sudden growth factor deprivation triggers apoptosis.
Although interactions with components of the extracellular
matrix provide anti-apoptotic signals to these adherent
ﬁbroblasts, serum removal for 24 hours results in more than
50% cell death, as determined by propidium iodide staining
(not shown). CCL39-Raf-1:ER cells express the fusion pro-
tein Raf-1:ER, therefore, addition of 4-hydroxytamoxifen
(4-HT) results in the selective and persistent activation of
Raf-1 signaling. 4-HT addition to serum-deprived cells leads
to a complete inhibition of apoptosis (data not shown,
[27, 28]). As shown in Figure 1(a),s e r u mr e m o v a lg r a d u a l l y
decreased the levels of phosphorylated MAPK1 and 3 (also
known as ERK1 and 2) and this was accompanied by the
appearance of the p35 and p37 cleavage products of pro-
caspase 9. The presence of 4-HT maintained phospho-
rylation of MAPK1,3 and completely inhibited caspase 9
cleavage.
Consistent with the fact that procaspase 9 cleavage is
generally associated with the generation of the active form
of caspase 9, we observed an increase in caspase 9 activity
in cell extracts prepared 14 hours after serum removal and
this activity was signiﬁcantly inhibited in the presence of
4-HT (Figure 1(b)). Caspase 3 is known to be a direct
substrate of caspase 9, accordingly its activation was also
found to be repressed upon Raf-1 stimulation (Figure 1(b)).
These results indicate that sustained Raf-1 activation inhibits
caspase 9 cleavage and activity following serum removal
thereby preventing apoptosis to proceed.
3.2. Caspase 9 Activation Is Inhibited by the MEK/MAPK1,3
Pathway. To determine the role of Map kinases in the inhi-
bition of caspase 9 cleavage, 4-HT-treated cells were incu-
bated with increasing concentrations of the speciﬁc MEK1
inhibitorsU0126,PD98059andPD184352.Allofthesephar-
macological agents prevented Raf-1-induced MAPK activa-
tion and reversed the cleavage of caspase 9 (Figure 2(a)).
4-HT-induced Raf-1:ER activation is dose-dependent, the
dose-response experiment shown in Figure 2(b) clearly
indicates a close relationship between MAPK phosphory-
lation and caspase 9 cleavage. It should be noted that
in exponentially growing cells, the inhibition of MEK by
U0126 was suﬃcient to induce a weak cleavage of caspase
9( Figure 2(c)), which is more pronounced at lower serum
concentration. Thus, we can conclude that the inhibition
of caspase 9 cleavage by Raf-1 depends on MEK activity4 Journal of Signal Transduction
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Figure 1: (a) Raf-1 activation inhibits caspase-9 cleavage upon serum withdrawal. CCL39-ΔRaf-1:ER cells treated with or without 4-HT
were deprived of serum for the indicated time periods. The cell lysates were analyzed by immunoblotting for caspase-9, phospho-MAPK1,3,
and total MAPK1. (b) Raf-1 activation inhibits caspase activity CCL39-ΔRaf-1:ER-cells treated or not with 4-HT were deprived of serum for
14 hours as indicated. sts: the eﬀect of 0.3mM staurosporin is shown as a comparison. Caspase 9 activity was measured using the peptide
LEHD-pNA as a substrate and caspase 3 activity using DEVD-pNA. The mean values ± SEM were calculated from at least two separate
experiments performed in triplicate.
and MEK activity contributes permanently to the protection
against caspase 9 activation provided by serum.
3.3. Caspase 9 Inhibition Requires Protein Synthesis and
Persistent MEK Activity. We then determined if the protec-
tive eﬀect of Raf-1 would require de novo protein synthe-
sis. Because cycloheximide has been shown to completely
prevent serum deprivation-induced apoptosis in CCL39-
derived lines (our unpublished observations and [28]), we
analyzed the eﬀect of emetine, another protein synthesis
inhibitor. As shown in Figure 3(a), addition of emetine
at the same time as 4-HT (lane 3, emetine at time 0)
completely blocked Raf-1-mediated caspase 9 inhibition,
without aﬀecting Raf-1-induced phosphorylation of MAPK.
Raf-1-mediated protection was still ineﬀective when emetine
was added two hours after 4-HT stimulation and was
graduallyrestoredwhenemetinewasaddedlater.Additionof
emetine 8 hours after Raf-1 activation (last lane Figure 3(a))
did not aﬀect inhibition of caspase 9 cleavage anymore
since only full-length procaspase 9 is detected. These results
indicate that Raf-1-mediated caspase 9 inhibition requires
protein synthesis and that complete protection is achieved
after 6–8 hours accumulation of a caspase 9 inhibitor. XIAP
is one of the potential inhibitors of caspase 9 downstream
cytochrome c release. Thus, we investigated the expression
of XIAP following 4-HT treatment of CCL39-ΔRaf-1:ER
cells and found that XIAP expression was not aﬀected by
Raf-1 activity or by emetine treatment (Figure 3(a)). These
results indicate XIAP is not the emetine-sensitive inhibitor
of caspase 9.
Caspase 9 processing have been shown to be regulated in
vitroby direct MAPK1,3 phosphorylation [26], to determine
if Raf-1/MAPK-mediated protection of caspase 9 cleavage
in intact cells was only a posttranslational mechanism we
determined the time course of Raf-1 action. Figure 3(b)
shows that delayed addition of U0126 after 4-HT as a
mean to terminate Raf-1/MAPK action resulted in caspase
9 cleavage. When U0126 was added 12, 10, or 8 hours after
4-HT and the experiment terminated at 24 hours, the cells
remained unprotected for 12, 14, and 16 hours, respectively.
Under these conditions, the extent of caspase 9 cleavage was
similar to that in cells that were maintained unprotected
for the same times because of delayed addition of 4-HT
(Figure 3(c)) This result indicates that 4HT preincubation
is not suﬃcient to prevent caspase 9 cleavage. Thus, caspase
9 protection requires both protein synthesis and continuous
Raf-1 signaling.
3.4. Raf-1/MAPK Activation Induces Posttranslational Mod-
iﬁcations of Caspase 9. The above-mentioned experiments
suggest the involvement of posttranslational mechanisms in
the protection of caspase 9 cleavage, we thus investigated the
role of the recently identiﬁed MAPK1,3 phosphorylation site
T125 present on caspase 9. Figure 4(a) shows the transient
expression of a myc tagged mutated form of caspase 9
in which T125 is substituted by the nonphosphorylatable
residue alanine. Serum withdrawal-induced cleavage of
caspase 9 T125A was totally prevented by 4-HT addition.
This results indicates that phosphorylation of T125 is not
involved in Raf-1/MAPK protection of caspase 9 cleavage.
In addition, two-dimensional electrophoresis analysis of
catalytically inactives capase 9 and mutant caspase 9 after
Raf-1 stimulation (Figure 4(b)) revealed that caspase T125A
was still able to shift in response to 4-HT addition. This
resultsuggeststhepresenceofanadditional phosphorylation
site on caspase 9. In the presence of 4-HT, caspase 9 clearlyJournal of Signal Transduction 5
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Figure 2: Raf-1-mediated caspase-9 inhibition depends on MEK activity. (a) CCL39-ΔRaf-1:ER cells were serum deprived for 24 hours in
the absence or presence of 1μM 4-HT. The indicated concentrations of the MEK inhibitors PD98059 and PD184352 were added 30 minutes
before 4-HT addition. The cell lysates were analyzed by immunoblotting for caspase-9, phospho-MAPK1,3, and total MAPK1. (b) Dose
response for U0126 at diﬀerent 4-HT concentrations. (c) Exponentially growing CCL39-ΔRaf-1:ER cells in the presence of 5% or 1% fetal
calf serum were treated for 24 hours with increasing concentrations of U0126.
showed an additional spot indicating that indeed T125 is
phosphorylatedinresponseto4-HT.Bothsitesweresensitive
to U0126.
3.5. Raf-1 Activation Does Not Prevent Cytochrome c Release.
The release of cytochrome c from mitochondria into the
cytosol is an important cellular event leading to caspase
9 processing. We, therefore, examined the distribution of
cytochrome c following serum removal in control and 4-
HT-treated cells by immunoﬂuorescence analysis. As shown
in Figure 5(a), control cells presented a typical punctuate
staining of cytochrome c corresponding to its mitochondrial
localization. After 14 hours of serum removal, 20% of the
cells exhibited a rounded morphology (cell marked with
asterisk on Figure 5(a)). Only the cells that remained adher-
ent were examined, and since apoptosis induces cell detach-
ment, these values are only indicative of the cell population
statusatagiventimepoint.Roundedcellspresentedadiﬀuse
cytochromecstainingandanintensiﬁcationofactivecaspase
3 labeling. Since caspase 3 is a direct caspase 9 substrate, the
presence of active caspase 3 is indicative of caspase 9 acti-
vation. Nuclear condensation was detected in 50% of these
cells, indicating that half the cells which released cytochrome
c, completed apoptosis 14 hours after serum withdrawal.
Interestingly, although 4-HT treatment inhibited caspase 3
activation and nuclear condensation after serum removal, it
did not interfere with cytochrome c release (cell marked with
arrow on Figure 5(a)). Rather, an increase in cells exhibiting
cytoplasmic cytochrome c was detected in 4-HT-treated
cells compared to nontreated cells (Figure 5(b)); this ﬁnding
indicates that Raf-1/MAPK prevents apoptosis to proceed in
the presence of cytosolic cytochrome c. The activation of
Raf-1 did not perturb mitochondrial localization in control,
serum-stimulated cells (not shown).
To conﬁrm that caspase 9 activation can be inhibited
in the presence of cytosolic cytochrome c, we performed
in vitro assays. Cytosolic extracts from cells deprived of
serum for 9 hours in the presence or absence of 4-HT
were incubated with 1μMc y t o c h r o m eca n d1 m MA T P
[32]. Incubation was performed at 20◦Ci no r d e rt oa v o i d
the rapid inactivation of MAPK observed at 37◦C( n o t
shown). As can be seen in Figure 6,c y t o c h r o m ec / A T P
addition induced caspase 9 cleavage in serum-deprived
cell extracts but not in extracts from 4-HT treated cells. A
similar result was obtain upon electroporation of puriﬁed
cytochrome c in intact cells that were preincubated with
4-HT (see Figure S1 in Supplementary material available
online at doi:10.1155/2011/834948). These results further
demonstrate that Raf-1 activation inhibits caspase 9 cleavage
downstream of mitochondrial cytochrome c release.6 Journal of Signal Transduction
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Figure 3: (a) Raf-1-mediated protection of caspase 9 cleavage
requires protein synthesis. CCL39-ΔRaf-1:ER cells were deprived of
serum for a total time of 24 hours in the presence or absence of
1μM 4-HT. The protein synthesis inhibitor emetine (20μM) was
added at the indicated time point. The cell lysates were analyzed by
immunoblotting for caspase-9, phospho-MAPK1,3, total MAPK1
and XIAP. (b) and (c) time course of Raf-1-mediated caspase 9
inhibition. (b) CCL39-ΔRaf-1:ER cells were deprived of serum for
a total time of 24 hours in the presence of 50nM 4-HT. 10μM
U0126 was added at the indicated time after serum withdrawal.
(c) Cells were deprived of serum for 24 h; 4-HT (1μM) was added
at the indicated time after serum withdrawal. The cell lysates were
analyzed by immunoblotting for caspase-9.
3.6. Raf-1 Activation Does Not Prevent Apoptosome Forma-
tion. In the cytosol of apoptotic cells, binding of cytochrome
c to APAF-1 leads to its oligomerization and recruitment of
procaspase9intoahighmolecularweightcomplexknownas
the apoptosome [8]. We examined whether Raf-1 activation
inhibited procaspase 9 activation in the cells by blocking
formation of the apoptosome. To do so size exclusion
chromatography was performed on cytosolic extracts of
CCL39-ΔRaf-1:ER cells followed by Western blot analysis of
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Figure 4: Mutation of threonine 125 does not prevent caspase
9 phosphorylation and cleavage inhibition. (a) CCL39-ΔRaf-1:ER
cells were transfected with the indicated construct (CD8 is used as a
transfection control) and 48 hours later were deprived of serum in
the presence or absence of 1μM 4-HT for 24 hours. The cell lysates
were analyzed by immunoblotting for myc and phospho-MAPK1,3.
(b) CCL39-ΔRaf-1:ER cells stably expressing myc-tagged C287S
(catalytically inactive) caspase 9 or C287S-T125A caspase 9 were
incubated for 2 hours with 1μM4 - H To r1 0μM U0126 in serum-
free medium. Total cells were lysed in 2D sample buﬀer containing
6M urea, resolved by two-dimensional gel electrophoresis, and
analyzed by immunoblotting for myc.
the diﬀerent apoptosome components. Results in Figure 7(a)
show that in lysates from control cells in presence of
serum, APAF-1 was located in fractions corresponding to
Mr of ∼200kDa–400kDa. In lysates from serum-deprived
cells, the APAF-1 signal shifted to fractions corresponding
to approximately Mr of ∼700kDa, consistent with the
f o r m a t i o no fa na c t i v ea p o p t o s o m ec o m p l e xin vivo [33].
In extracts from serum-stimulated cells, cytochrome c was
not detected in fractions containing high molecular weight
complex. However, following serum removal, cytochrome c
coeluted with APAF-1 in high molecular weight fractions
(Figure 7(b)). Raf-1 activation does not interfere with the
relocalization of APAF-1 and cytochrome c into high molec-
ular weight complexes upon serum withdrawal (Figures 7(a)
and 7(b)), these results suggest that Raf-1 activation does
not interfere with the apoptosome formation. The presence
of cytochrome c in the high molecular weight fractions also
conﬁrm that Raf-1 activation does not block cytochrome c
release. We then determined if caspase 9 present in livingJournal of Signal Transduction 7
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Figure 5: (a) Raf-1 activity does not prevent cytochrome c release. CCL39-ΔRaf-1:ER cells were deprived of serum for 14 hours in the
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Figure 6: Raf-1 activation prevents cytochrome c/ATP-mediated
activation of caspase 9. CCL39-ΔRaf-1:ER cells were deprived of
serumfor9hoursinthepresenceorabsenceof4-HT.Thecellswere
lysed in hypotonic buﬀer and the cell lysates were incubated with
1μM cytochrome c and 1mM ATP for the indicated times. The cell
lysates were analyzed by immunoblotting for caspase-9, phospho-,
and total MAPK1,3.
cells was recruited into the apoptosome (Figure 7(c))a n d
found that under all conditions, most of the caspase 9 signal
was detected in fractions corresponding to Mr of ∼60kDa to
150kDa. This in contrast to results obtained after activation
in cell extracts where the cleaved caspase 9 is mainly present
in the high molecular weight fractions (see Supplementary
Figure S2) and indicates that the active caspase 9 is rapidly
released from the apoptosome in vivo. However, a small
caspase signal could be detected in the high molecular
weightfractionsthatcouldbeenhancedbyconcentratingthe
eluat. As shown in Figure 7(d), a higher resolution of high
molecular weight fractions revealed the presence of caspase
9. Some procaspase 9 was found in the ∼700kDa fractions
of serum containing cell, while its amount increased notably
in high molecular weight fractions from serum-deprived
cells. The ∼700kDa fractions from serum-starved cells also
contained the cleaved form of caspase 9. In 4-HT-treated
serum-deprived cells, a large amount of procaspase 9, but
not cleaved caspase 9, was found in the ∼700kDa fractions.
These results indicate that in intact CCl39 cells, the majority
of caspase 9 is not associated with APAF-1 and that Raf-1
activity, while preventing caspase 9 cleavage, does not inhibit
the pool of caspase 9 that is transiently recruited into the
apoptosome.
Altogether,theseresultsindicatethattheRaf-1/MAPK1,3
pathway controls the cleavage of caspase 9 within the
apoptosome.
4. Discussion
Growth factor deprivation is often linked to activation of the
mitochondrial pathway of apoptosis because overexpression
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Figure 7: (a) and (b): Raf-1 activity does not interfere with
apoptosome formation. CCL39-ΔRaf-1:ER cells growing in 7.5%
FCS (control) were deprived of serum (−S) for 14 hours in the
presence or absence of 4-HT. The lysates were separated by gel
ﬁltration chromatography on a sephacryl S300 column previously
calibrated with the indicated molecular weight standards. Samples
fromhighmolecularweightfractionsweredilutedwith4XLaemmli
buﬀer and were analyzed by immunoblotting for the presence of
APAF-1 (a) and cytochrome c (b). (c) and (d): recruitment of
caspase 9 in the apoptosome. (c) The conditions are the same as
in Figures 7(a) and 7(b); samples are a pool of 2 fractions and
were analyzed by immunoblotting for caspase 9. pro: procaspase 9,
47kd. p37, p35: cleaved caspase 9. (d) Recruitment of caspase 9 in
highmolecularweightfractions.Detailedanalysisofhighmolecular
weight fractions from Figure 7(c).Journal of Signal Transduction 9
of Bcl2 prevents caspase activation. However, very few
reports have documented caspase 9 activation in intact cells.
In this paper, we clearly show that caspase 9 is activated
and cleaved following serum deprivation of exponentially
growing CCL39 cells. Activation of Raf-1:ER by 4-HT leads
to the speciﬁc activation of the MEK/MAPK1,3 signaling
module [27] and prevents caspase 9 activation. A panel
of MEK inhibitors inhibits the eﬀects of Raf-1:ER. Since
U0126 and PD98059 also inhibit MEK5/ERK5, a pathway
involved in Raf-1 signaling [34], we used PD184161 a
speciﬁc MEK1,2 inhibitor [35] at low concentrations [36]t o
show that the MEK/MAPK1,3 pathway mediates caspase 9
inhibition. Treatment of exponentially growing CCL39 cells
by MEK inhibitor was suﬃcient to cause the appearance of
the p35 and p37 processed caspase 9 products. This ﬁnding
suggests that MEK activity participates in serum-mediated
cell protection and that high levels of MAPK activity are
continually required to maintain caspase 9 inactive. Serum
deprivation of CCl39 cells has often been used to study cell
cycle regulation [37]. To arrest CCL39 cells in G0/G1 and
limit cell death upon serum deprivation, cells were usually
grown to conﬂuency during several days, the progressive
limitation in nutrients resulting in an adaptation of cells
to growth factor deprivation. Growth factor deprivation
aﬀects nutrient utilization and induces a metabolic arrest
that results in apoptosis [14]. It is thus possible that sudden
growth factor deprivation has a more pronounced eﬀect in
actively growing cells than in quiescent cells with limited
nutrient needs. Indeed, most quiescent cells in serum-
deprived medium are alive and can reenter the cell cycle,
while about 65% of an actively growing cell population
dies upon serum removal. This observation might be
relevant to tumor cell biology since tumor cells need to
maintain a high metabolic rate with limited survival factors.
Pharmacological inhibition of MEK activity has been shown
to induce cell death in exponentially growing cell lines
derived from melanoma [38], leukemia [17], ﬁbrosarcoma,
and renal carcinoma [39]. It remains to be determined if
MEK inhibitors would induce caspase 9 cleavage in tumor
cells.
Our immunoﬂuorescence and in vitro caspase 9 activa-
tion assays show that Raf-1-mediated inhibition of caspase
9 occurs at a postcytochrome c release level. The ability of
MAPK pathway to prevent apoptosis progression following
cytochrome c release has been described in several other
cell models. For example, Raf1:ER activation inhibits cell
detachment-induced apoptosis in MDCK cells [40]a n d
MEK inhibits caspase 3 activation in serum-deprived Rat1
ﬁbroblasts [23] or in etoposide-treated small cell lung cancer
cells [24]. Moreover, MEK activity also blocks cytochrome c-
inducedcaspase3activityinXenopusandRat1ﬁbroblastcell
freeextracts[23,41].Invivo,acidicpHinducedaverysimilar
mechanism of inhibition of caspase 9 processing without
impaired cytochrome c release or APAF-1 interaction [42].
NGFs have been shown to mediate neuron resistance to
apoptosis in response to cytochrome c microinjection in
the cytosol [43]. This observation led to the notion of a
“competence to die” induced by growth factor withdrawal;
our results indicate that Raf-1/MAPK inactivation would
render cells competent to respond to cytosolic cytochrome
c and then to die.
There is a large body of evidence indicating that
MAPK1,3 signaling is involved in the regulation of mito-
chondria homeostasis. For instance, p90rsk phosphorylates
and inactivates the proapoptotic protein, Bad [21, 44] while
direct phosphorylation of the anti-apoptotic protein Bcl2
by MAPK1,3 results in its stabilization and enhanced cell
survival [19]. These ﬁndings indicate that the MAPK1,3
pathway inhibits apoptosis by preventing cytochrome c
release,anhypothesisthathasnotbeendirectlydocumented.
Indeed, CCL39 cells are sensitive to the anti-apoptotic
properties of Bcl2 family proteins because stable expression
of BclXl prevents caspase activation upon anchorage and
serum withdrawal (our unpublished observations). Thus,
under our stringent conditions of apoptosis induction, the
putative control of mitochondrial integrity by MAPK1,3 is
not eﬃc i e n te n o u g ht op r e v e n tc y t o c h r o m ecr e l e a s e .I n
CCL39 Raf1:ER cells, Cook and colleagues clearly demon-
strated that MAPK-induced degradation of Bim by the
proteasome resulted in Bax inactivation [28, 45]. However,
downregulation of Bim has not been shown to inhibit
cytochrome c release in CCL39 cells, an event that could
be regulated by other MAPK-insensitive BH3-containing
proteins.
Our analysis of apoptosome by gel ﬁltration chro-
matography indicated that the protective eﬀect of MAPK1,3
pathway does not interfere with APAF-1 multimerization or
caspase 9 recruitment. However, even in apoptotic condi-
tions, most of the caspase 9 was located in low molecular
weight fractions. Most of the publications illustrating the
recruitmentofcaspase 9in the apoptosome areperformedin
vitro [46] in the presence of exogenously added cytochrome
c and ATP and it is not known how much caspase 9 is
associated with multimerized APAF-1 in vivo. Since present
models of caspase 9 activation indicate that only a minor
portion of puriﬁed caspase 9 is found in the active dimeric
form [12] it is perhaps not surprising to ﬁnd little caspase
9 in high molecular weight complexes in vivo.H o w e v e r ,
when Raf-1/MAPK is activated there is a clear increase
in the recruitment of the procaspase 9 to the 700kDa
complex. Recruitment of procaspase 9 is thought to favor
a homodimerization step where a monomer provides, the
structural constraints required for the constitution of a
functionalcatalyticcleft[47].Thissubsequentlyresultsinthe
autoproteolysis of the link between the large and the small
catalytic subunits. Since caspase 9 is not cleaved in 4-HT-
treated cells, we can conclude that Raf-1 activation is likely
to interfere with the formation of an active dimer.
Our results indicate that protein synthesis is required for
caspase 9 inhibition. Among the potential inhibitors of the
apoptosome,heat-shockproteinsarenotlikelytobeinvolved
in Raf-1-induced caspase 9 inhibition, because they interfere
either with APAF-1 oligomerization or caspase 9 recruitment
[48, 49]. Similarly, an other negative regulator of apoptosis,
the oncoprotein prothymosin α is not a likely mediator
of Raf-1 eﬀects because it prevents apoptosome formation
[9] however, the same study identiﬁed PHAP as positive
regulator of caspase 9 activation in the apoptosome. It is not10 Journal of Signal Transduction
yet known whether proteins of the PHAP family are required
for caspase 9 activation in intact cells and then would be
regarded as potential targets of Raf-1/MAPK activity. The
major inhibitor of caspase 9 is XIAP. XIAP inhibits the
catalytic activity of caspase 9 by using its BIR3 domain to
heterodimerize with a caspase 9 monomer through the same
interface that is required for the caspase 9 homodimerization
[12]. However, caspase 9/XIAP interaction also requires the
cleavage of caspase 9 because the newly generated small sub-
unit N-terminal stabilizes the interaction [50]. Since caspase
9 is not cleaved in the presence of activated Raf-1, a stable
interaction between caspase 9 and XIAP is not expected,
however, overexpression of XIAP by inhibiting newly gener-
ated cleaved caspase 9 would prevent further autoprocessing
of procaspase monomers In mammals, MAPK activation
has been associated with the increase of XIAP expression in
melanoma cells [51], monocytes [52]a n dJ u r k a tc e l l s[ 53].
In small-cell lung cancer cells, Downward and colleagues
have demonstrated that FGF2 inhibits etoposide-mediated
caspase 3 activation downstream cytochrome c [24]. It was
found that MAPK1,3 activation by FGF2 inhibits the release
of Smac from mitochondria. Since Smac triggers the protea-
somaldegradationofXIAP,MAPactivationresultedinXIAP
stabilization. In our hands, XIAP was not induced following
Raf-1 activation, as it would be expected if Smac were
retained in the mitochondria. Moreover, XIAP levels were
insensitive to emetine, an indication that XIAP is not the
emetine sensitive anti-apoptotic protein required for Raf-1-
mediated caspase 9 protection. We cannot exclude that Raf-1
activity up regulates XIAP anti-apoptotic eﬀect by inducing
a cofactor that could enhance caspase 9/XIAP interaction;
however, we were not able to coimmunoprecipitate caspase
9 and XIAP in cell extracts from 4-HT treated cells (data not
shown).
Clarke and colleagues reported that MAPK pathway
directly controls caspase 9 activation in vitro by phospho-
rylation on its residue Thr125. Although Thr125 phospho-
rylation of caspase 9 through a MEK-dependent mechanism
occurs in PMA treated HeLa cells [26], it has not yet been
linked with cell survival. In serum-deprived CCL39 cells
expressing a human caspase 9 mutated on its phosphoryla-
tion site (caspase 9 T125A), we show that MAPK activation
isstillabletoinhibit thecleavageofthismutant.Thus,itmay
be argued that phosphorylation of caspase 9 on threonine
125 is not involved in MAPK-mediated caspase 9 inhibition
inserum-deprivedcells.However,wecannotexcludethatthe
inhibition of endogenous caspase 9 by phosphorylation on
T125 interferes with the cleavage of the mutated form within
heterodimers despite the fact that caspase 9 T125A was
overexpressed by transient transfection. Our 2D gel analysis
indicatesthatcaspase9T125A stillshiftsin responsetoRaf-1
activation,anindicationthatitisphosphorylatedonanother
residue. We can exclude S196 a site phosphorylated by AKT
[54] because this site present on human caspase 9 is not
conservedinrodents[55]andRaf-1:ERdoesnotactivateAkt
in CCl39 cells [27]. Caspase 9 is also phosphorylated by PKA
[56], but since PKA is not inhibited by U0126 [57], it is not
likely to be involved because U0126 totally prevents caspase
shifts on 2D gels. However, we cannot exclude that this
MEK-dependent charge shift results from the synthesis or
processing of an autocrine ligand [58] that does not activate
the PI3K pathway [27], yet activates other sigalling pathway
leading to caspase 9 phosphorylation (reviewed in [59]).
The role of caspase 9 phosphorylation remains to be
clariﬁed, since procaspase 9 activation requires an obligatory
dimerization step provided by homophilic contact between
the catalytic subunits, this region of the caspase could be a
site of interaction with a putative inhibitor of dimerization
or a site of direct phosphorylation.
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